named programs · 4 · from sources
What they call their work
Correlative Science Initiative
Integrates biomarker analysis and genomic profiling into clinical trials to better understand treatment response and resistance mechanisms.
ITOG Annual Meeting
Annual scientific forum for global thyroid cancer experts to share research, discuss clinical challenges, and shape future trials and collaborations.
ITOG Clinical Trials Program
Facilitates phase I/II trials of targeted therapies like selpercatinib and lenvatinib for RET-mutant and anaplastic thyroid cancers, often in collaboration with academic centers.
Robert F. Gagel ITOG Discovery Award
Grants funding to support innovative research proposals in thyroid cancer, such as Jim Fagin, MD’s work on cGAS-STING activation in anaplastic thyroid cancer.
activities · 4 groups
What they do
-
Cancer Research Funding 2 activities
- Conducting and facilitating clinical trials for thyroid cancer therapiesDesigns, sponsors, and conducts multicenter and international clinical trials to evaluate novel therapies for medullary, differentiated, anaplastic, and radioiodine-refractory thyroid cancers, including phase I/II and phase II studies of selpercatinib, lenvatinib, cabozantinib, and selumetinib, with findings contributing to FDA approvals and clinical practice.
- Funding thyroid cancer research and supporting young investigatorsProvides research grants and awards, including the Robert F. Gagel ITOG Discovery Award, to support innovative studies in thyroid cancer, funds correlative and translational research, and empowers emerging specialists through targeted funding and training opportunities.
-
-
Biomedical Research and Innovation 1 activity
- Advancing thyroid cancer research through scientific collaboration and leadershipProvides strategic leadership and fosters global scientific collaboration to advance thyroid oncology, including convening expert panels to establish evidence-based guidelines for mutational testing and publishing position statements on integrating genomic profiling into clinical trials.
-
-
Medical Research & Education Dissemination 1 activity
- Disseminating research and educational content to the medical community and publicHosts annual meetings, roundtables, and virtual sessions to share emerging research, delivers expert lectures at international conferences, and distributes newsletters summarizing clinical trials, registry updates, and member achievements in thyroid cancer.
-
-
Uncategorized 1 activity
- Building organizational and research capacity in thyroid oncologyFormalized governance through bylaws and a board structure, supports trainees and emerging specialists through mentorship and fellowship development, and strengthens the field by uniting international experts to improve care for rare and advanced thyroid cancers.
-
financials · form 990 · fy2024
revenue
Total revenue$542K
Contributions & grants$283K52%
Program service revenue$00%
Investment income$259K48%
Other revenue$0
expenses
Total expenses$361K
Program expenses63%
Admin / overhead37%
Fundraising0%
Salaries & benefits$0
Grants paid out$56K
Largest expense lineOther
balance sheet
Total assets$4.34M
Cash$1.22M
Investments$3.12M
Liabilities$5K
Net assets$4.34M
Liquid reserves144.3 mo
5 years on record · 2020–2024 · YoY revenue +42.8%
leadership · form 990 part vii · fy2024
Who runs it
board members · 14
- ALAN HO MD PHD — CORRELATIVE CHAIR
- CARMELLO NUCERA — DIRECTOR
- CHRISTINE SPITZWEG — DIRECTOR
- DWIGHT VICKS III MBA — CFO/ CO-FOUNDER
- FRANK WORDEN MD — PROTOCOL COMMITTE CHAIR
- GREGORY RANDOLPH MD — PRESIDENT
- IAN GANLEY MD PHD — DIRECTOR
- JULIE ANN SOSA MD — FINANCE CHAIR
- LAURA BOUCAI MD — SECRETARY
- LAURA FUGAZZOLA — DIRECTOR
- LINDSEY BISCHOFF MD — DIRECTOR
- NAIFA BUSAIDY MD — DIRECTOR
- SARIMAR AGOSTO SALGADO MD — DIRECTOR
- VICTOR MERNET MD — DIRECTOR
relationships · 36
Who they work with
- ACCRU Partner — Collaborates with ACCRU, a clinical trials group organized by Mayo Clinic, to conduct clinical trials.
- American Head and Neck Society Endocrine Surgery Section Partner — Collaborated with ITOG to convene a multidisciplinary expert panel and establish consensus on mutational testing in advanced thyroid cancer.
- BIDMC/Harvard Medical School Partner — Hosts ITOG member Carmelo Nucera, MD, PhD
- Beth Israel Deaconess Medical Center Partner — Host institution for board member with expertise in thyroid oncology.
- Children's Hospital of Philadelphia Partner — Hosts ITOG members Aime T. Franco, MD and Andrew J. Bauer, MD
- City of Hope Partner — Host site for the ITOG Annual Meeting
- City of Hope Comprehensive Cancer Center Partner — Hosts ITOG member Amy Y. Chen, MD
- FDA Government — Regulatory body whose approval of new therapies has been supported by ITOG-led clinical trials.
- Fujian Medical University Union Hospital Partner — Hosts ITOG member Bo Wang, MD
- Harvard Medical School Partner — Academic affiliate of board member contributing to ITOG's scientific leadership.
- Harvard Medical School Partner — Institution represented by Executive Committee member Gregory W. Randolph
- Hoag Newport Hospital Partner — Hosts ITOG member Chaitali Nangia, MD
- Hospital de Clínicas de Porto Alegre Partner — Hosts ITOG member Ana Luiza Maia, MD
- ICESP/University of Sao Paulo / Hospital Vila Nova Star, Rede D'OR Partner — Hosts ITOG member Ana O. Hoff, MD
- King Faisal Specialist Hospital & Research Centre Partner — Hosts ITOG member Ali S. Alzahrani, MD
- MD Anderson Cancer Center Partner — Host institution for board member serving as Membership Committee Chair.
- Mass Eye and Ear Partner — Institution represented by Executive Committee member Gregory W. Randolph
- Mayo Clinic Rochester Partner — Hosts ITOG member Ashish Chintakuntlawar, MD
- Memorial Sloan-Kettering Partner — Hosts ITOG member Alan Ho, MD, PhD
- Memorial Sloan-Kettering Cancer Center Partner — Collaborates on the ITOG Selumetinib Trial with Principal Investigator Alan Ho, MD.
- Moffitt Cancer Center Partner — Hosts ITOG member Christine Chung, MD
- Ohio State University Partner — Hosts ITOG member Bhavana Konda, MD
- Perelman School of Medicine, University of Pennsylvania Partner — Hosts ITOG member Andrew J. Bauer, MD
- STANFORD UNIVERSITY Partner — Hosts ITOG member Alexander D. Colevas, MD
- School of Medicine. Universidad de Antioquia Partner — Hosts ITOG member Alejandro Roman, MD
- The University of Colorado Cancer Center Partner — Collaborates with ITOG on funded thyroid cancer research.
- The University of Colorado Cancer Center Partner — Partners with ITOG on research led by Principal Investigator Bryan Haugen.
- The University of Texas MD Anderson Cancer Center Partner — Hosts ITOG member Anastasios Maniakas, MD
- ThyCa: Thyroid Cancer Survivors’ Association Partner — Receives memorial donations through ITOG in honor of Dr. Bryan McIver.
- University Hospital Munich, LMU Munich Partner — Hosts ITOG member Christine Spitzweg, MD
+ 6 more
strategies · 6
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Global Scientific Collaboration Networkmethodology: global_collaborationBy connecting international experts to share data, best practices, and strategic vision, ITOG accelerates thyroid cancer research because distributed expertise and coordinated governance reduce duplication and amplify discovery potential.
- Integration of Translational Research into Clinical Trialsmethodology: translational_research_integrationBy embedding biomarker analysis and genomic profiling within clinical trials, ITOG links biological insights to clinical outcomes because this integration enables faster identification of effective therapies and accelerates therapeutic discovery.
- Mentorship for Research Capacity Buildingmethodology: mentorship_pipelineBy mentoring emerging clinicians and scientists, ITOG builds long-term capacity for thyroid cancer research because sustained progress depends on cultivating the next generation of experts.
- Multidisciplinary, Patient-Centered Collaborationmethodology: patient-centered_multidisciplinary_approachBy integrating endocrinologists, surgeons, oncologists, and basic scientists in a patient-centered framework, ITOG advances thyroid cancer research and clinical trial design because diverse expertise aligned around patient needs produces more innovative and clinically relevant outcomes.
- Research and Knowledge Disseminationmethodology: research-and-educationBy conducting scientific research and sharing findings through educational forums, ITOG advances progress toward cures because open dissemination strengthens collective understanding and drives further innovation.
- Strategic Industry-Academic Engagementmethodology: bidirectional_scientific_engagementBy structuring bidirectional collaboration between industry and academic leaders, ITOG aligns innovation with trial development and patient accrual because shared goals and integrated planning accelerate progress toward cures.